Press release
Global Homozygous Familial Hypercholesterolemia (HoFH) Market Size, Share, Trend, Growth, Analysis and Forecast Report 2016 - Acute Market Reports
The report provides comprehensive information on the therapeutics under development for Homozygous Familial Hypercholesterolemia (HoFH), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Homozygous Familial Hypercholesterolemia (HoFH) and features dormant and discontinued projects.
Browse Full Report Visit - http://www.acutemarketreports.com/report/homozygous-familial-hypercholesterolemia-hofh-pipeline-review-h1-2016
Acute Market Reportss report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Acute Market Reportss proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Browse All Reports of This Category - http://www.acutemarketreports.com/category/healthcare-market
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Homozygous Familial Hypercholesterolemia (HoFH)
- The report reviews pipeline therapeutics for Homozygous Familial Hypercholesterolemia (HoFH) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Homozygous Familial Hypercholesterolemia (HoFH) therapeutics and enlists all their major and minor projects
- The report assesses Homozygous Familial Hypercholesterolemia (HoFH) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Homozygous Familial Hypercholesterolemia (HoFH)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Homozygous Familial Hypercholesterolemia (HoFH)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Homozygous Familial Hypercholesterolemia (HoFH) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Get Complete Report @ Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H1 2016
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Acute Market Reports Report Coverage 6
Homozygous Familial Hypercholesterolemia (HoFH) Overview 7
Therapeutics Development 8
Pipeline Products for Homozygous Familial Hypercholesterolemia (HoFH) - Overview 8
Homozygous Familial Hypercholesterolemia (HoFH) - Therapeutics under Development by Companies 9
Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Homozygous Familial Hypercholesterolemia (HoFH) - Products under Development by Companies 13
Homozygous Familial Hypercholesterolemia (HoFH) - Companies Involved in Therapeutics Development 14
Aegerion Pharmaceuticals, Inc. 14
CymaBay Therapeutics, Inc. 15
Kastle Therapeutics LLC 16
Regeneron Pharmaceuticals, Inc. 17
RegenxBio Inc. 18
Homozygous Familial Hypercholesterolemia (HoFH) - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
AEM-28 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
AEM-2802 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
AEM-2814 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
AM-0010 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
evinacumab - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
gemcabene calcium - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
lomitapide mesylate - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
MBX-8025 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
MGL-3196 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
MGL-3745 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
mipomersen sodium - Drug Profile 43
Product Description 43
Mechanism of Action 43
Contact Us :
Chris Paul
ACUTE MARKET REPORTS
Office No 101, 1st Floor ,
Aditi Mall, Baner,
Pune, MH, 411045
India
Toll Free(US/CANADA): +1-855-455-8662
India: +91 7755981103
Email : sales@acutemarketreports.com
Website : http://www.acutemarketreports.com
About - Acute Market Reports :
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements.We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.
Our team consists of highly motivated market research professionals and they are accountable for creating the groundbreaking technology that we utilize in our search engine operations to easily recognize the most current market research reports online.
Office No 101, 1st Floor , Aditi Mall, Baner,
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Homozygous Familial Hypercholesterolemia (HoFH) Market Size, Share, Trend, Growth, Analysis and Forecast Report 2016 - Acute Market Reports here
News-ID: 372511 • Views: …
More Releases from Acute Market Reports
Pediatric Allergy Treatment Market Set to Soar: Projected to Reach $13.9 Billion …
The pediatric allergy treatment market is experiencing significant growth, driven by the rising prevalence of allergic conditions among children. Allergies, including food allergies, allergic rhinitis, asthma, and skin allergies, are becoming increasingly common in the pediatric population. This trend has led to a growing demand for effective treatment options that can provide relief and improve the quality of life for children affected by these conditions. The market for pediatric allergy…
Strippable Coatings Market Is Expected To Expand At A CAGR Of 7.1% From 2024 To …
Strippable coatings, also referred to as peelable coatings, are a type of non-flammable, water-based protective solution that can be easily removed from surfaces without the need for harsh chemical strippers or cleaners. Composed of water-based acrylic polymers, vapor phase corrosion inhibitors, and a thixotropic thickener, these coatings enhance barrier and surface protection properties. They can be applied via brush, spray, dip, or roll and are primarily utilized on bare metal…
Bakeware Market | Global Industry Size, Development Strategy, Revenue Analysis, …
The market for bakeware is a dynamic and evolving sector that serves both commercial and residential consumers. In 2023, the bakeware market was valued at $3,850.0 million and is projected to reach $6,462.2 million by the end of 2032. This market is anticipated to grow at a compound annual growth rate (CAGR) of 5.91% during the forecast period from 2024 to 2032. The growth is largely driven by a resurgence…
Global Wire Harness Market Set to Expand Through 2032 with Major Growth Drivers …
The global wire harness market is poised for robust growth, with a projected compound annual growth rate (CAGR) of 5.8% from 2024 to 2032. This growth trajectory is primarily driven by significant advancements in the automotive sector, escalating demand within consumer technology, and increasing applications in aerospace and defense sectors.
In the automotive industry, the wire harness market has seen substantial growth, primarily fueled by the advent of electric vehicles (EVs)…
More Releases for Familial
Homozygous Familial Hypercholesterolemia Market Outlook 2024-2034
Introduction
Homozygous familial hypercholesterolemia (HoFH) is a rare, life-threatening genetic disorder characterized by extremely high cholesterol levels from birth. Patients with HoFH are at a very high risk of premature atherosclerotic cardiovascular disease (ASCVD), often developing complications as early as childhood. While the condition is rare-affecting approximately 1 in 160,000 to 300,000 individuals globally-it has become a major focus for pharmaceutical innovation due to the severity of the disease and the…
Familial Adenomatous Polyposis (FAP) Therapeutics- Pipeline Analysis 2018
Familial adenomatous polyposis (FAP) is a genetic disorder, characterized by the development of adenomatous colon polyps in the intestinal tract, resulting in colon cancer. The disease is diagnosed when more than 100 adenomatous colon polyps are developed in a person.
Download the sample report at: https://www.pharmaproff.com/request-sample/1025
A person with FAP is at a high risk of developing cancer of small intestines or stomach. This disease is categorized into three types including attenuated…
Heterozygous Familial Hypercholesterolemia (heFH) Therapeutics - Pipeline Analys …
Heterozygous familial hypercholesterolemia (HeFH) is an inherited genetic disorder that affects the body’s ability to control cholesterol. It is characterized by very high LDL (low density lipoprotein) cholesterol (above 190 for adults or above 160 for children) and family history of high cholesterol, heart disease or stroke.
Download the sample report @ https://www.pharmaproff.com/request-sample/1135
A very high level of LDL from birth leads to a twenty-fold increase in the risk of premature…
Familial Amyloid Cardiomyopathy Treatment Market Opportunity Analysis, 2018–20 …
Aggregation and deposition of mutant and wild-type transthyretin protein (TTR) in heart results in familial amyloid cardiomyopathy, which typically occur after age of 60. Familial amyloid cardiomyopathy is also known as hereditary cardiac transthyretin amyloidosis or hereditary amyloid cardiomyopathy. The protein transthyretin amyloid fibrils infiltrate the myocardium that leads to diastolic dysfunction from restrictive cardiomyopathy, which eventually result to heart failure. There are several mutation in TTR which are associated…
Familial Adenomatous Polyposis Pipeline Therapeutics Development Market Review 2 …
RnRMarketResearch.com adds “Familial Adenomatous Polyposis - Pipeline Review, H1 2017” to its store providing an overview of the Familial Adenomatous Polyposis therapeutic pipeline with comprehensive information on the therapeutic development for Familial Adenomatous Polyposis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews…
Familial Adenomatous Polyposis - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Familial Adenomatous Polyposis - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Familial Adenomatous Polyposis - Pipeline Review, H1 2017, provides an overview of the Familial Adenomatous Polyposis (Genetic Disorders) pipeline landscape.
Familial adenomatous polyposis (FAP) is also known as familial polyposis coli, adenomatous polyposis coli, or…
